<SEC-DOCUMENT>0001183740-23-000087.txt : 20230712
<SEC-HEADER>0001183740-23-000087.hdr.sgml : 20230712
<ACCEPTANCE-DATETIME>20230712165533
ACCESSION NUMBER:		0001183740-23-000087
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230712
FILED AS OF DATE:		20230712
DATE AS OF CHANGE:		20230712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRIGHT MINDS BIOSCIENCES INC.
		CENTRAL INDEX KEY:			0001827401
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40997
		FILM NUMBER:		231085173

	BUSINESS ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		6474072515

	MAIL ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k.htm
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXY7CNC5JSVVG3MSDDP]. www.edgarsuite.com -->
<HEAD>
<TITLE>UNITED STATES</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>UNITED STATES</B><BR><B>SECURITIES AND EXCHANGE COMMISSION</B><BR><B>Washington, D.C. &nbsp;20549</B></P>
<P align=center style='font:14pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>FORM 6-K</B></P>
<P align=center style='font:12pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>For the month of <B>July 2023</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Commission File No. <B>001-40997</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><FONT style='font-size:13pt;border-bottom:1px solid #000000'><B>BRIGHT MINDS BIOSCIENCES INC.</B></FONT><BR>(Translation of registrant's name into English)</P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>19 Vestry Street,</B><BR><FONT style='border-bottom:1px solid #000000'><B>New York, NY &nbsp;10013</B></FONT><BR>(Address of principal executive office)</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F</P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>Form 20-F</B>&#160;&#160;<B>[ X ]</B> &nbsp;Form 40-F<B>&#160;&#160;[ &nbsp;]</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) &#160;[ &nbsp;]</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) &#160;[ &nbsp;]</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0;background-color:#FFFFFF'><A name=_DV_M0 /><B>SUBMITTED HEREWITH</B></P>
<TABLE align=center style=border-collapse:collapse;width:475.45pt><TR><TD valign=top style=width:56.95pt><P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:5.4pt;color:#000000'><FONT style='border-bottom:1px solid #000000'><B>Exhibits</B></FONT></P>
</TD><TD valign=top style=width:418.5pt><P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:4.5pt;margin-right:7.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:56.95pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:5.4pt;color:#000000'>99.1</P>
</TD><TD valign=top style=width:418.5pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:2.6pt;margin-right:1.95pt;color:#000000'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=ex991-20230712.htm style=text-decoration:none>News Release dated </A><A href=ex991-20230712.htm style=text-decoration:none>July 1</A><A href=ex991-20230712.htm style=text-decoration:none>1</A><A href=ex991-20230712.htm style=text-decoration:none>, 2023</A></FONT></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>SIGNATURE</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'><B>BRIGHT MINDS BIOSCIENCES INC.</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'><I>/s/ Ryan Cheung</I><BR>__________________________<BR>Ryan Cheung<BR>Chief Financial Officer</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Date:  July 12, 2023</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-20230712.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXY7CNC5JSVVG3MSDDP]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt'><IMG src=ex99120230712_1.jpg width=113 height=88 alt=image1.png title=image1.png>&nbsp;</P>
<P align=center style='font:15pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'><A name=_DV_M113 /><A name=_DV_M114 /><A name=_DV_M115 /><B>Bright Minds Announces Effective Date of Share Consolidation</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'><A name=_DV_M119 />Vancouver, British Columbia, July 11, 2023 &#8211;&nbsp;Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (&#8220;<B>Bright Minds</B>&#8221; or the &#8220;<B>Company</B>&#8221;), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that, further to its news release on June 22, 2023, the Company will consolidate its common shares (the &#8220;<B>Common</B> <B>Shares</B>&#8221;) on a five (5) to one (1) basis (the &#8220;<B>Consolidation</B>&#8221;). </P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>The Company&#8217;s post-Consolidation Shares are expected to begin trading on the Canadian Securities Exchange and The NASDAQ Capital Market on July 14, 2023. The name of the Company and trading symbol will remain the same after the Consolidation. &nbsp;Following the Consolidation, the Company&#8217;s CUSIP number will be 10919W405 and the new ISIN number will be CA10919W4056.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>No fractional Common Shares will be issued upon the Consolidation. In the event a holder of Common Shares would otherwise be entitled to receive a fractional Common Share in connection with the Consolidation, the number of Common Shares to be received by such shareholder will be rounded down to the next whole number if that fractional Common Share is less than one half (1/2) of a Common Share, and will be rounded up to the next whole number of Common Shares if that fractional Common Share is equal to or greater than one half (1/2) of a Common Share.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>Letters of transmittal with respect to the Consolidation will be mailed to all registered shareholders of the Company. All registered shareholders will be required to send their respective certificates representing the pre-Consolidation Common Shares along with a properly executed letter of transmittal to the Company&#8217;s transfer agent, Computershare Investor Services Inc. (&#8220;<B>Computershare</B>&#8221;), in accordance with the instructions provided in the letter of transmittal. Additional copies of the letter of transmittal can be obtained through Computershare at <FONT style='border-bottom:1px solid #000000'><B>1-800-564-6253</B></FONT>. All shareholders who submit a duly completed letter of transmittal along with their respective pre-Consolidation Common Share certificate(s) to Computershare will receive a post-Consolidation Common Share certificate or Direct Registration Advice representing the post-Consolidation Common Shares. </P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'><B>About Bright Minds</B></P>
<P align=justify style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'>Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds&#8217; drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'><B>Investor Contacts:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>Lisa Wilson</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#0000FF'><FONT style=color:#000000>E: </FONT><FONT style='border-bottom:1px solid #0000FF'>lwilson@insitecony.com</FONT></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>T: 917-543-9932</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>Ian McDonald</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>CEO and Director</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>E: <FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>ian@brightmindsbio.com</FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#7A7A7A'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'><I>This news release includes certain statements that may be deemed &#8220;forward-looking statements&#8221;. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;potential&#8221; and similar expressions, or that events or conditions &#8220;will&#8221;, &#8220;would&#8221;, &#8220;may&#8221;, &#8220;could&#8221; or &#8220;should&#8221; occur. Forward-looking statements in this news release include, without limitation, statements related to the completion of the Consolidation. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company&#8217;s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.</I></P>
<P align=justify style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'><I>Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release.</I></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99120230712_1.jpg
<TEXT>
begin 644 ex99120230712_1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< '<# 2(  A$! Q$!_\0
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MGZW=36T8N!*B(5&W[Q)]ZTK/PYX;M_BVJ6VFV,5Q/HKRWEFD:LD;^;'M;&,
MG+#C&<9KRNY^*.NV^G^&-%TK2M3M=8TME>>%E8"Z&WE3&!G:>3TX%:=A\3-/
M@^)U[KUCX1UC^T+BR-O>62 ,V\,A$F,9' P>/3WH T-)M](^'WP^L_$D>BVN
MI:YK5\886N -D6]VVC./E4*O..23Z=-*_P!$U2Z\>^$-3UGPOH>GQ&Z:WGDM
M)%E-P[1N1D;1\H"GKDY[UPOA'XC!]*NO".N^%9]=TP2O+%!"A:: %R2"/8GK
MD$9Q6JGQ0AN;W0['PWX,OET;0[K[0T,6Z27<5D4+QD*,NQY))Q0!V6G?"NYM
MOC#<^)IO[*?1Y&D*V@&6 ,>T?)MV]>>M5/!_B6SOOB9J?@N3PYI?D6UQ=L+K
MR5+G$C$#&,=\?05YM%X[DT+XPW'B^_T;4(()C(RV<WR/\R;>XQ[TG@[Q?-#\
M6-4\5V6@:CJ$=PT[_9;5"[H)&R,X!H J?%'QE'K^I2Z1'H=CIZZ9>S1B6V7#
M2@$KSQ[9KSRM3Q')-/XEU.YGM)[1[BZDF\B=2KH&8L 0?K670 4444 %%%%
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
